From Casetext: Smarter Legal Research

In re Omeprazole Patent Litigation

United States Court of Appeals, Federal Circuit
Mar 8, 2011
412 F. App'x 297 (Fed. Cir. 2011)

Opinion

No. 2010-1414.

March 8, 2011.

Appeal from the United States District Court for the Southern District of New York in Nos. 00-CV-6749, 03-CV-6057, M-21-81, and MDL no. 1291, Judge Barbara S. Jones.

Errol B. Taylor, Milbank, Tweed, Hadley McCloy LLP, of New York, NY, argued for plaintiffs-appellees. With him on the brief were Fredrick M. Zullow, John M. Griem, Jr., and Christopher J. Gaspar.

James H. Wallace, Jr., Wiley Rein, LLP, of Washington, DC, argued for defendants-appellants. With him on the brief were Mark A. Pacella and Brian H. Pandya.

Before RADER, Chief Judge, MOORE and O'MALLEY, Circuit Judges.


JUDGMENT


THIS CAUSE having been heard and considered, it is

ORDERED and ADJUDGED:

AFFIRMED. See Fed. Cir. R. 36.


Summaries of

In re Omeprazole Patent Litigation

United States Court of Appeals, Federal Circuit
Mar 8, 2011
412 F. App'x 297 (Fed. Cir. 2011)
Case details for

In re Omeprazole Patent Litigation

Case Details

Full title:In re OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle…

Court:United States Court of Appeals, Federal Circuit

Date published: Mar 8, 2011

Citations

412 F. App'x 297 (Fed. Cir. 2011)

Citing Cases

In re Wellbutrin XL Antitrust Litig. Indirect Purchaser Class

See AstraZeneca AB v. Mylan Labs., Inc. , No. 00-cv-6749, 2010 WL 2079722, at *4 (S.D.N.Y. May 19, 2010)…

Endo Pharm. Inc. v. Amneal Pharm., LLC

In this District, "[v]ideo fees have been deemed taxable where 'there was an expectation among the parties…